Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders

Conditions studied

Psychosis, Depression

About this study

Not only being the mainstay of treatment for schizophrenia spectrum psychotic disorders, antipsychotics, especially the second-generation antipsychotics (SGAs) have also been recommended as augmenting agents for treating depression. Dopaminergic agents, including both dopamine D2/D3 antagonists and dopamine partial D2 agonists, have been effective for treating psychosis and schizophrenia. Amongst all SGAs, those with partial D2 agonistic property are generally acknowledged to have better side-effect profiles with lower incidence of extrapyramidal side-effects, prolactin increase, weight gain, QTc prolongation, and metabolic syndrome, as well as more efficacious in alleviating depressive symptoms. Up-to-date, three SGAs, namely aripiprazole, brexpiprazole and cariprazine, are known to possess such partial D2 agonism. ReSD-HK study is part of the ReSD Asian Study aiming to carefully evaluate a cohort of patients prescribed with brexpiprazole on its efficacy and tolerability as treatment for schizophrenia and/or depression in a real-life clinical setting.

Interventions

• Drug: Brexpiprazole — Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders

Primary outcomes

• Change in Brief Psychiatric Rating Scale-24 in 6 months (6 months)
• Change in Clinical Global Impression in 6 months (6 months)
• Change in Beck Anxiety Inventory in 6 months (6 months)
• Change in Beck Depression Inventory in 6 months (6 months)
• Change in Digital Symbol Substitution Test in 6 months (6 months)
• Change in World Health Organization Disability Assessment Schedule 2.0 in 6 months (6 months)

Eligibility information

Study locations

• Queen Mary Hospital, Hong Kong, 000000 Hong Kong